Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomized Study EVERHEART

被引：0
|
作者：
Potena, L. [1 ]
Barberini, F. [1 ]
Boffini, M. [2 ]
Amarelli, C. [3 ]
Pellegrini, C. [4 ]
Livi, U. [5 ]
Masciocco, G. [6 ]
Faggian, G. [7 ]
Gerosa, G. [8 ]
Lilla, P. [9 ]
Marraudino, N. [10 ]
Porcu, M. [11 ]
Guarisco, R. [12 ]
Maccherini, M. [13 ]
机构：
[1] AO S Orsola Malpighi, Bologna, Italy
[2] ASO Molinette S Giovanni Battista, Turin, Italy
[3] Osped Monaldi, Naples, Italy
[4] Policlin San Matteo, I-27100 Pavia, Italy
[5] AOU S Maria Misericordia, Udine, Italy
[6] AO Niguarda Ca Granda, Milan, Italy
[7] Osped Civile, I-37126 Verona, Italy
[8] AOU Padova, Padua, Italy
[9] AO San Camillo Forlanini, Rome, Italy
[10] Policlin Bari, Bari, Italy
[11] AO G Brotzu, Cagliari, Italy
[12] Novartis Farma, Origgio, VA, Italy
[13] AOU Senese, Siena, Italy
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2013年 / 32卷 / 04期
关键词：
D O I：
10.1016/j.healun.2013.01.303
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
352
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [41] INCIDENCE OF INTERSTITIAL LUNG DISEASE WITH EVEROLIMUS IN TWO LARGE, RANDOMIZED, MULTICENTER STUDIES IN DE NOVO HEART OR KIDNEY TRANSPLANT RECIPIENTS
    Lopez, P.
    Shand, N.
    Tufa, M.
    Cibrik, D.
    Lehmkuhl, H.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 58 - 58
  • [42] PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPPRESSIVE THERAPY FOR DE NOVO KIDNEY TRANSPLANT RECIPIENTS IN RUSSIA
    Avxentyev, N. A.
    Derkach, E., V
    Prokopenko, E., I
    VESTNIK TRANSPLANTOLOGII I ISKUSSTVENNYH ORGANOV, 2019, 21 (01): : 23 - 34
  • [43] Efficacy and Safety of Everolimus with Early Reduction or Elimination of Tacrolimus in 719 de Novo Liver Transplant Recipients - Results at 12 Months
    De Simone, P.
    Nevens, F.
    Duvoux, C.
    Koneru, B.
    McCormack, L.
    McCaughan, G.
    Navasa, M.
    Dong, G.
    Hexham, J. M.
    Junge, G.
    Fung, J.
    TRANSPLANTATION, 2012, 94 (10) : 750 - 750
  • [44] Effect of Everolimus Based Immunosuppression on De Novo Heart Transplant Recipients-24 Months Efficacy and Safety Results from A2310 Study
    Kobashigawa, J.
    Pauly, D.
    Kfoury, A.
    Ross, H.
    Wang, S. -S.
    Cantin, B.
    van Bakel, A.
    Starling, R.
    Hirt, S.
    Dong, G.
    Panis, C.
    Lopez, P.
    Eisen, H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 67 - 68
  • [45] EFFECT OF EARLY CONVERSION TO EVEROLIMUS ON CARDIOVASCULAR PARAMETERS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM THE ELEVATE STUDY
    Holdaas, Hallvard
    Van Der Giet, Markus
    De Fijter, Johan W.
    Speziale, Antonio
    Escrig, Cesar
    Junge, Guido
    Wang, Zailong
    Cruzado, Josep M.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 209 - 210
  • [46] Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal in Heart Transplant Recipients: A Randomized Trial
    Andreassen, A. K.
    Andersson, B.
    Gustafsson, F.
    Eiskjaer, H.
    Rdegran, G.
    Gude, E.
    Jansson, K.
    Solbu, D.
    Sigurdardottir, V.
    Arora, S.
    Dellgren, G.
    Gullestad, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (08) : 1828 - 1838
  • [47] Exposure to CsA, and not to everolimus, is associated with impaired renal function in de novo heart transplant recipients.
    Varnous, Shaida
    Livi, Ugolino
    Poncelet, Alain
    Delgado, Juan
    Vermes, Emmanuelle
    Li, Yulan
    Arizon, Jose
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 346 - 346
  • [48] Design and Baseline Data from Hephaistos Study Evaluating Efficacy and Safety of Early Initiation of Everolimus With Reduced Tacrolimus in De Novo Liver Transplant Recipients
    Nashan, Bjorn
    Schemmer, Peter
    Braun, Felix
    Dworak, Markus
    Wimmer, Peter
    Schlitt, Hans
    TRANSPLANTATION, 2015, 99 : 214 - 215
  • [49] Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now?
    Zuckermann, Andreas
    Wang, Shoei-Shen
    Epailly, Eric
    Barten, Markus J.
    Sigurdardottir, Vilborg
    Segovia, Javier
    Varnous, Shaida
    Turazza, Fabio M.
    Potena, Luciano
    Lehmkuhl, Hans B.
    TRANSPLANTATION REVIEWS, 2013, 27 (03) : 76 - 84
  • [50] Everolimus Treatment Reduces the Need for Anti-CMV Prophylaxis in De Novo Heart Transplant Recipients
    Potena, L.
    Bianchi, I. G.
    D'Agostino, C.
    Abate, D.
    Magnani, G.
    Chiereghin, A.
    Grigioni, F.
    Gambino, A.
    Toscano, G.
    Sgarabotto, D.
    Gerosa, G.
    Branzi, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S64 - S64
12345